E. Magherini

发表

Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.

C. Perou, T. Nielsen, M. Cheang, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Resection of previously unresectable liver metastases from colorectal cancer (LMCRC) after chemotherapy (CT) with CPT-11/L-OHP/LV5FU (Folfirinox): A prospective phase II trial

M. Ychou, B. Nordlinger, M. Rivoire, 2004 .

Resection of previously unresectable liver metastases from colorectal cancer (LMCRC) after chemotherapy (CT) with CPT-11/L-OHP/LV5FU (Folfirinox): A prospective phase II trial.

M. Ychou, B. Nordlinger, M. Rivoire, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials.

E. Van Cutsem, P. Rougier, D. Cunningham, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III study.

Y. Ba, Jianming Xu, R. Lim, 2018, Future oncology.

A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study.

J. Machiels, M. Campone, X. Pivot, 2011, European journal of cancer.

Comparison of the tolerance and efficacy of LV5FU2-CPT11 and FOLFIRI regimens in front-line treatment of advanced colorectal cancer -A pooled analysis of 254 patients included in 2 randomised trials.

C. Tournigand, P. Rougier, D. Cunningham, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reply to R.S. Mehta et al

C. Perou, T. Nielsen, M. Cheang, 2009 .

A Randomized, Double-blind, Placebo-controlled Study to Assess QTc Interval Prolongation of Standard Dose Aflibercept in Cancer Patients Treated With Docetaxel

J. Machiels, P. Maison-Blanche, D. Strumberg, 2013, Journal of cardiovascular pharmacology.

Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand.

M. Peyromaure, S. Oudard, F. Scotté, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Assessment of frozen glove use in the prevention of docetaxel induced onycholysis and cutaneous reaction. Results of a multicenter case-control study

M. Peyromaure, S. Oudard, F. Scotté, 2004 .

Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study.

T. Conroy, G. Deplanque, J. Metges, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.

Thierry Gil, Camilla Thellenberg Karlsson, I. Tannock, 2013, The Lancet. Oncology.

Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level.

M. Ducreux, J. Taïeb, V. Boige, 2006, European journal of cancer.

A multicenter phase II study of cisplatin and docetaxel (Taxotere) in the first-line treatment of advanced ovarian cancer: a GINECO study

B. Weber, V. Diéras, J. Ferrero, 2004, Cancer Chemotherapy and Pharmacology.

Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial.

E. Van Cutsem, P. Ruff, G. van Hazel, 2018, Journal of geriatric oncology.

A dose-escalating study of XRP6258 in combination with capecitabine, in patients (pts) with metastatic breast cancer (MBC) progressing after anthracycline and taxane therapy: Preliminary results.

J. Machiels, M. Campone, X. Pivot, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Aflibercept versus placebo in combination with docetaxel/prednisone for first-line treatment of men with metastatic castration-resistant prostate cancer (mCRPC): Results from the multinational phase III trial (VENICE).

B. Tombal, V. Matveev, G. Gravis, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

5025 A dose escalating study of cabazitaxel (XRP6258) in combination with capecitabine, in patients (pts) with metastatic breast cancer (MBC) progressing after anthracycline and taxane therapy

J. Machiels, M. Campone, X. Pivot, 2009 .

Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials.

E. Van Cutsem, P. Rougier, D. Cunningham, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.